CY1108720T1 - Διαρυλ υποκατεστημενα τριαζολια ως αναστολεις διαυλου νατριου - Google Patents
Διαρυλ υποκατεστημενα τριαζολια ως αναστολεις διαυλου νατριουInfo
- Publication number
- CY1108720T1 CY1108720T1 CY20091100054T CY091100054T CY1108720T1 CY 1108720 T1 CY1108720 T1 CY 1108720T1 CY 20091100054 T CY20091100054 T CY 20091100054T CY 091100054 T CY091100054 T CY 091100054T CY 1108720 T1 CY1108720 T1 CY 1108720T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- pain
- alone
- pharmaceutically acceptable
- effective amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ενώσεις διαρυλ υποκατεστημένου τριαζολίου που αντιπροσωπεύονται από τον Τύπο I, II ή III, ή φαρμακευτικώς αποδεκτά άλατα αυτών, και διεργασία κατασκευής τέτοιων ενώσεων και αλάτων αυτών. Οι φαρμακευτικές συνθέσεις περιλαμβάνουν αποτελεσματική ποσότητα των τρεχουσών ενώσεων, είτε μόνων, είτε σε συνδυασμό με μια ή περισσότερες άλλες θεραπευτικώς δραστικές ενώσεις, και φαρμακευτικώς αποδεκτό φορέα. Μέθοδοι καταστάσεων θεραπείας που σχετίζονται με, ή προκαλούνται από, δραστικότητα διαύλου νατρίου, που συμπεριλαμβάνουν, για παράδειγμα, οξύ πόνο, χρόνιο πόνο, εντοσθιακό πόνο, φλεγμονώδη πόνο, νευρασθενικό πόνο, επιληψία, σύνδρομο ευερέθιστου εντέρου, κατάθλιψη, άγχος, σκλήρυνση κατά πλάκας, και διπολική διαταραχή, που περιλαμβάνουν χορήγηση αποτελεσματικής ποσότητας των παρουσών ενώσεων, είτε μόνων, είτε σε συνδυασμό με μια ή περισσότερες άλλες θεραπευτικώς δραστικές ενώσεις. Μέθοδος χορήγησης τοπικής αναισθησίας αποτελείται από χορήγηση αποτελεσματικής ποσότητας ένωσης της τρέχουσας εφεύρεσης, είτε μόνης, είτε σε συνδυασμό με μια ή περισσότερες άλλες θεραπευτικώς δραστικές ενώσεις, και φαρμακευτικώς αποδεκτό φορέα.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45595203P | 2003-03-18 | 2003-03-18 | |
| EP04720360A EP1606269B1 (en) | 2003-03-18 | 2004-03-12 | Biaryl substituted triazoles as sodium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108720T1 true CY1108720T1 (el) | 2013-09-04 |
Family
ID=33030073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100054T CY1108720T1 (el) | 2003-03-18 | 2009-01-15 | Διαρυλ υποκατεστημενα τριαζολια ως αναστολεις διαυλου νατριου |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7326726B2 (el) |
| EP (1) | EP1606269B1 (el) |
| JP (1) | JP4482554B2 (el) |
| KR (1) | KR100737721B1 (el) |
| CN (2) | CN101289428A (el) |
| AR (1) | AR044503A1 (el) |
| AT (1) | ATE412639T1 (el) |
| AU (1) | AU2004221885C1 (el) |
| BR (1) | BRPI0408407A (el) |
| CA (1) | CA2519252C (el) |
| CL (1) | CL2004000551A1 (el) |
| CY (1) | CY1108720T1 (el) |
| DE (1) | DE602004017438D1 (el) |
| DK (1) | DK1606269T3 (el) |
| EC (1) | ECSP056018A (el) |
| EG (1) | EG25994A (el) |
| ES (1) | ES2314387T3 (el) |
| HR (1) | HRP20050816A2 (el) |
| IS (1) | IS8001A (el) |
| JO (1) | JO2480B1 (el) |
| MA (1) | MA27665A1 (el) |
| MX (1) | MXPA05009847A (el) |
| MY (1) | MY142651A (el) |
| NO (1) | NO20054775L (el) |
| NZ (1) | NZ542205A (el) |
| PE (1) | PE20041066A1 (el) |
| PL (1) | PL1606269T3 (el) |
| PT (1) | PT1606269E (el) |
| RU (1) | RU2356897C2 (el) |
| SI (1) | SI1606269T1 (el) |
| TW (1) | TWI337605B (el) |
| UA (1) | UA81660C2 (el) |
| WO (2) | WO2004083190A1 (el) |
| ZA (1) | ZA200506906B (el) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1587821E (pt) | 2002-12-19 | 2008-09-23 | Scripps Research Inst | Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina |
| AR044503A1 (es) * | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| WO2005047270A2 (en) * | 2003-11-10 | 2005-05-26 | Merck & Co., Inc. | Substituted triazoles as sodium channel blockers |
| WO2005113523A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| BRPI0807972A2 (pt) * | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
| PL2118077T3 (pl) | 2007-02-08 | 2015-05-29 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| WO2008154484A1 (en) | 2007-06-08 | 2008-12-18 | Mannkind Corporation | Ire-1a inhibitors |
| DK2464645T3 (en) | 2009-07-27 | 2017-10-23 | Gilead Sciences Inc | CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS |
| CN103096977B (zh) | 2010-07-02 | 2017-02-15 | 吉利德科学公司 | 作为离子通道调节剂的稠杂环化合物 |
| WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| NO3175985T3 (el) | 2011-07-01 | 2018-04-28 | ||
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| SG2014013270A (en) | 2011-09-16 | 2014-05-29 | Pfizer | Solid forms of a transthyretin dissociation inhibitor |
| WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2014152738A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Lxr modulators |
| US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
| US11192856B2 (en) | 2017-10-05 | 2021-12-07 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
| BR112020018403A2 (pt) * | 2018-03-09 | 2020-12-22 | Pi Industries Ltd. | Compostos heterocíclicoscomo fungicidas |
| CN108794413A (zh) * | 2018-06-25 | 2018-11-13 | 青岛科技大学 | 一种1,2,4-三氮唑-3-甲酰胺的合成方法 |
| CN108863965A (zh) * | 2018-06-25 | 2018-11-23 | 青岛科技大学 | 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US875782A (en) * | 1907-04-29 | 1908-01-07 | Walter H Cook | Fast-nut. |
| TW226993B (el) * | 1992-05-29 | 1994-07-21 | Kumiai Chemical Industry Co | |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| IT1292091B1 (it) * | 1997-06-05 | 1999-01-25 | Geange Ltd | Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| WO2000057877A1 (en) * | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| MXPA03009846A (es) * | 2001-04-27 | 2004-05-05 | Vertex Pharma | Derivados de triazol inhibidores de cinasa y usos de los mismos. |
| US6797722B2 (en) * | 2002-05-03 | 2004-09-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases |
| KR101120337B1 (ko) * | 2002-07-09 | 2012-02-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법 |
| KR100467668B1 (ko) * | 2002-08-07 | 2005-01-24 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| KR100470075B1 (ko) * | 2002-11-21 | 2005-02-05 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| AR044503A1 (es) * | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| WO2005047270A2 (en) * | 2003-11-10 | 2005-05-26 | Merck & Co., Inc. | Substituted triazoles as sodium channel blockers |
-
2004
- 2004-03-11 AR ARP040100789A patent/AR044503A1/es unknown
- 2004-03-11 MY MYPI20040842A patent/MY142651A/en unknown
- 2004-03-12 NZ NZ542205A patent/NZ542205A/en not_active IP Right Cessation
- 2004-03-12 AT AT04720360T patent/ATE412639T1/de active
- 2004-03-12 AU AU2004221885A patent/AU2004221885C1/en not_active Ceased
- 2004-03-12 CA CA002519252A patent/CA2519252C/en not_active Expired - Fee Related
- 2004-03-12 CN CNA2008101000997A patent/CN101289428A/zh active Pending
- 2004-03-12 JP JP2006507122A patent/JP4482554B2/ja not_active Expired - Fee Related
- 2004-03-12 PL PL04720360T patent/PL1606269T3/pl unknown
- 2004-03-12 MX MXPA05009847A patent/MXPA05009847A/es active IP Right Grant
- 2004-03-12 ES ES04720360T patent/ES2314387T3/es not_active Expired - Lifetime
- 2004-03-12 KR KR1020057017327A patent/KR100737721B1/ko not_active IP Right Cessation
- 2004-03-12 WO PCT/US2004/007830 patent/WO2004083190A1/en active Application Filing
- 2004-03-12 PT PT04720360T patent/PT1606269E/pt unknown
- 2004-03-12 US US10/799,230 patent/US7326726B2/en active Active
- 2004-03-12 CN CNA200480013089XA patent/CN1788002A/zh active Pending
- 2004-03-12 DE DE602004017438T patent/DE602004017438D1/de not_active Expired - Lifetime
- 2004-03-12 SI SI200430959T patent/SI1606269T1/sl unknown
- 2004-03-12 WO PCT/US2004/007597 patent/WO2004083189A1/en active Application Filing
- 2004-03-12 RU RU2005132168/04A patent/RU2356897C2/ru not_active IP Right Cessation
- 2004-03-12 DK DK04720360T patent/DK1606269T3/da active
- 2004-03-12 BR BRPI0408407-1A patent/BRPI0408407A/pt not_active IP Right Cessation
- 2004-03-12 EP EP04720360A patent/EP1606269B1/en not_active Expired - Lifetime
- 2004-03-12 UA UAA200509759A patent/UA81660C2/ru unknown
- 2004-03-14 JO JO200430A patent/JO2480B1/en active
- 2004-03-16 PE PE2004000280A patent/PE20041066A1/es not_active Application Discontinuation
- 2004-03-17 CL CL200400551A patent/CL2004000551A1/es unknown
- 2004-03-17 TW TW093107083A patent/TWI337605B/zh not_active IP Right Cessation
-
2005
- 2005-08-29 IS IS8001A patent/IS8001A/is unknown
- 2005-08-29 ZA ZA200506906A patent/ZA200506906B/xx unknown
- 2005-09-06 MA MA28481A patent/MA27665A1/fr unknown
- 2005-09-14 EC EC2005006018A patent/ECSP056018A/es unknown
- 2005-09-16 HR HR20050816A patent/HRP20050816A2/hr not_active Application Discontinuation
- 2005-09-18 EG EGNA2005000548 patent/EG25994A/xx active
- 2005-10-17 NO NO20054775A patent/NO20054775L/no not_active Application Discontinuation
-
2008
- 2008-01-30 US US12/011,967 patent/US7572822B2/en not_active Expired - Lifetime
-
2009
- 2009-01-15 CY CY20091100054T patent/CY1108720T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108720T1 (el) | Διαρυλ υποκατεστημενα τριαζολια ως αναστολεις διαυλου νατριου | |
| CY1121853T1 (el) | Συνδυαστικη θεραπεια για την αγωγη του διαβητη | |
| MXPA05010185A (es) | Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk. | |
| EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
| CY1106674T1 (el) | Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους | |
| IS8438A (is) | Setin tríasól sem natríum gangahemla | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| CY1110013T1 (el) | Συνδυασμοι για θεραπεια πολλαπλου μυελωματος | |
| EA200200509A1 (ru) | Новые производные бензоимидазола, используемые в качестве антипролиферативного средства | |
| NO20075134L (no) | Bestemte substituerte amider, fremgangsmate for femstilling derav og anvendelse derav | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| ATE440603T1 (de) | 8-hydroxychinolinderivate | |
| PA8509301A1 (es) | Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias | |
| WO2004045523A3 (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
| DE602004011394D1 (en) | Thiazolderivate | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| EP1177791A3 (en) | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | |
| ATE401901T1 (de) | Antikrebs- und antivirale zusammensetzung | |
| GB0202337D0 (en) | Cancer treatment | |
| BR0112123A (pt) | Composto | |
| DE69917809D1 (de) | Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz | |
| WO2006119402A3 (en) | C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth | |
| ATE336237T1 (de) | Aryl-n-cyanoguanidine derivate und deren verwendung | |
| EA200401432A1 (ru) | Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков |